169 related articles for article (PubMed ID: 30971669)
1. [A case of Crohn's disease complicated by Guillain-Barrè syndrome during ustekinumab therapy].
Fukushima T; Nakajima K; Nozawa H; Nishino H; Sugita A; Koganei K; Futatsuki R; Yamaguchi S; Asano S; Matsushima M
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(4):324-329. PubMed ID: 30971669
[TBL] [Abstract][Full Text] [Related]
2. Guillain-Barrè syndrome after treatment with human anti-tumor necrosis factorα (adalimumab) in a Crohn's disease patient: case report and literature review.
Cesarini M; Angelucci E; Foglietta T; Vernia P
J Crohns Colitis; 2011 Dec; 5(6):619-22. PubMed ID: 22115384
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of hidradenitis suppurativa in the setting of Crohn disease with combination adalimumab and ustekinumab.
Cline A; Pichardo RO
Dermatol Online J; 2019 Sep; 25(9):. PubMed ID: 31738849
[TBL] [Abstract][Full Text] [Related]
4. Case Report: Malignant melanoma in a patient with Crohn's disease treated with ustekinumab.
Axiaris G; Ioannou A; Papoutsaki M; Marinos L; Liontos M; Michopoulos S; Zampeli E
F1000Res; 2022; 11():424. PubMed ID: 37867623
[TBL] [Abstract][Full Text] [Related]
5. Successful Treatment With Ustekinumab for Enterocutaneous Fistulas in Crohn's Disease.
Madarame A; Kimura H; Kunisaki R
J Crohns Colitis; 2020 May; 14(4):569-570. PubMed ID: 31616911
[No Abstract] [Full Text] [Related]
6. Guillain-Barré syndrome during adalimumab therapy for Crohn´s disease: coincidence or consequence?
Cançado GG; Vilela EG
Scand J Gastroenterol; 2017 Apr; 52(4):473-476. PubMed ID: 27931132
[TBL] [Abstract][Full Text] [Related]
7. Ustekinumab treatment for neutrophilic dermatoses associated with Crohn's disease: A multicenter retrospective study.
de Risi-Pugliese T; Seksik P; Bouaziz JD; Chasset F; Moguelet P; Gornet JM; Bourrier A; Amiot A; Beaugerie L; Francès C; Guégan S;
J Am Acad Dermatol; 2019 Mar; 80(3):781-784. PubMed ID: 30003991
[No Abstract] [Full Text] [Related]
8. Ustekinumab in a patient with pyoderma gangrenosum and refractory Crohn's disease.
García Cámara P; Zubiri Ara ML; García López S
Med Clin (Barc); 2019 Oct; 153(8):e35-e36. PubMed ID: 30795905
[No Abstract] [Full Text] [Related]
9. Refractory Pyoderma Gangrenosum in a Patient With Crohn's Disease: Complete Response to Ustekinumab.
Nunes G; Patita M; Fernandes V
J Crohns Colitis; 2019 May; 13(6):812-813. PubMed ID: 30535292
[No Abstract] [Full Text] [Related]
10. Successful Therapy of Crohn's Disease-Associated Pulmonary Necrobiotic Nodules on Ustekinumab Therapy.
Ganzleben I; Hirschmann S; Köhler J; Fuchs FS; Rieker RJ; Baer E; Klenske E; Nagore D; Neurath MF; Atreya R
Am J Gastroenterol; 2020 Apr; 115(4):632-634. PubMed ID: 32149778
[No Abstract] [Full Text] [Related]
11. Metastatic Cutaneous Crohn's Disease of the Face-A Case Successfully Treated With Ustekinumab.
Martins Figueiredo L; Oliveira AM; Martins A
J Crohns Colitis; 2020 Jul; 14(6):874-875. PubMed ID: 31630151
[No Abstract] [Full Text] [Related]
12. Two Cases of Successful Ustekinumab Treatment for Non-infectious Uveitis Associated With Crohn's Disease.
Chateau T; Angioi K; Peyrin-Biroulet L
J Crohns Colitis; 2020 May; 14(4):571. PubMed ID: 31606743
[No Abstract] [Full Text] [Related]
13. Guillain-Barré syndrome and Crohn disease: a case report.
Yanagida H; Sugimoto K; Izu A; Wada N; Sakata N; Takemura T
J Child Neurol; 2014 Sep; 29(9):NP78-80. PubMed ID: 24092893
[TBL] [Abstract][Full Text] [Related]
14. [Ustekinumab for the treatment of Crohn's disease -Indication of Ustekinumab according to efficacy and safety].
Ishihara S; Kawashima K; Kinoshita Y
Nihon Shokakibyo Gakkai Zasshi; 2019; 116(3):216-223. PubMed ID: 30853674
[No Abstract] [Full Text] [Related]
15. Duodenal stenosis surgical treatment in Crohn's disease.
Chóliz Ezquerro J; Aparicio López D; García López S; Hörndler Argárate C; Serradilla Martín M
Rev Esp Enferm Dig; 2023 Dec; 115(12):733-734. PubMed ID: 36926950
[TBL] [Abstract][Full Text] [Related]
16. Ustekinumab for treatment of cutaneous Crohn's disease.
Abdat R; Markova A; Farraye FA; Lichtman MK
Dermatol Online J; 2016 Oct; 22(10):. PubMed ID: 28329588
[TBL] [Abstract][Full Text] [Related]
17. Efficiency of Ustekinumab in Crohn's Disease with Severe Psoriasiform Rash Induced by Biotherapies in an Adolescent.
Bertrand V; El Haite A; Carré D
Pediatr Dermatol; 2017 Jul; 34(4):e214-e215. PubMed ID: 28436109
[TBL] [Abstract][Full Text] [Related]
18. Cost-Effectiveness Comparison of Ustekinumab, Infliximab, or Adalimumab for the Treatment of Moderate-Severe Crohn's Disease in Biologic-Naïve Patients.
Aliyev ER; Hay JW; Hwang C
Pharmacotherapy; 2019 Feb; 39(2):118-128. PubMed ID: 30565265
[TBL] [Abstract][Full Text] [Related]
19. Number needed to treat and cost per remitter for biologic treatments of Crohn's disease in Japan.
Ueno F; Doi M; Kawai Y; Ukawa N; Cammarota J; Betts KA
J Med Econ; 2020 Jan; 23(1):80-85. PubMed ID: 31294641
[No Abstract] [Full Text] [Related]
20. Ustekinumab is effective and safe in the treatment of Crohn's disease refractory to anti-TNFα in an orthotopic liver transplant patient.
Martínez-Montiel M; Piedracoba-Cadahia P; Gómez-Gómez C; Gonzalo J
J Crohns Colitis; 2015 Sep; 9(9):816-7. PubMed ID: 26071409
[No Abstract] [Full Text] [Related]
[Next] [New Search]
